Evidence map›Paper›PMID 41903221›Full record

ArticleInternational health2026

Programmatic implications of the efficiency of uptake of Onchocerca volvulus microfilariae by Simulium sp. vectors.

Daniel A Boakye, Mike Y Osei-Atweneboana, Simon K Atta, Irene A Larbi, Charles D Mackenzie

Abstract read
In one paragraph

Article in International health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel A BoakyeRLMF, The END Fund, New York, NY 10016, USA.
Mike Y Osei-AtweneboanaCouncil for Scientific and Industrial Research, Water Institute, Box M32, Accra, Ghana.
Simon K AttaMedical School, University of Ghana, Box LG25, Legon, Accra, Ghana.
Irene A LarbiNoguchi Institute, University of Ghana, Box LG 581, Accra, Ghana.
Charles D MackenzieRLMF, The END Fund, New York, NY 10016, USA.ORCID 0000-0003-4628-8188

Funding

Bill & Melinda Gates Foundation OPP1193778Noguchi Memorial Institute for Medical ResearchReaching the Last Mile Fund (RLMF)
6 · The paper itself

Abstract

backgroundThe current global aim for onchocerciasis is to eliminate transmission of infection by administering ivermectin once a year or biannually. However, when ivermectin treatment is given annually for 9-10 y, some individuals still carry low microfilariae (mf) levels, which may allow continued transmission.

methodsAt four different times (0, 8, 90, 365 days) after treatment with ivermectin, 1608 newly emerged Simulium sanctipauli (Pra form) flies were fed on 35 volunteers, with initial dermal microfilarial loads ranging from 0 to >30 Onchocerca volvulus mf/mg skin. Ten days after feeding, the number and load of mf in these flies were assessed by dissection.

resultsNotably, even at the lowest skin-snip mf densities-including those showing zero infection-flies can still ingest O. volvulus mf and become infected; 29% of the 1608 fed flies picked up mf. The lowest skin mf levels were recorded on Day 90 after treatment, at which time vector mf uptake increased by 21% with every unit increase in skin mf density (P < .000).

conclusionsVery low dermal mf levels can still support parasite transmission. Consequently, widespread low O. volvulus infection in human populations with highly productive vector-breeding sites could significantly affect efforts to eliminate transmission.

Indexed as

Insect VectorsIvermectinMicrofilariaeOnchocerca volvulusOnchocerciasisSimuliidaeAnimalsFemaleHumansMaleSkinIvermectindermal microfilariaeeliminationfly feedingonchocerciasisskin snipping

Identifiers

PMID41903221
PMCPMC13223558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.